Metformin is Protective Against the Development of Mood Disorders

Abstract

Introduction Mood disorders are a major cause of disability, and current treatment options are inadequate for reducing the burden on a global scale. The aim of this project was to identify drugs suitable for repurposing to treat mood disorders.

Methods This mixed-method study utilized gene expression signature technology and pharmacoepidemiology to investigate drugs that may be suitable for repurposing to treat mood disorders.

Results The transcriptional effects of a combination of drugs commonly used to treat mood disorders included regulation of the steroid and terpenoid backbone biosynthesis pathways, suggesting a mechanism involving cholesterol biosynthesis, and effects on the thyroid hormone signaling pathway. Connectivity Map analysis highlighted metformin, an FDA-approved treatment for type 2 diabetes, as a drug having global transcriptional effects similar to the mood disorder drug combination investigated. In a retrospective cohort study, we found evidence that metformin is protective against the onset of mood disorders.

Discussion These results provide proof-of-principle of combining gene expression signature technology with pharmacoepidemiology to identify potential novel drugs for treating mood disorders. Importantly, metformin may have utility in the treatment of mood disorders, warranting future randomized controlled trials to test its efficacy.

Key words

metformin - mood disorder - pharmacoepidemiology - drug repurposing - gene expression signature

^* These authors contributed equally.

Publication History

Received: 09 May 2022
Received: 25 August 2022

Accepted: 09 August 2022

Article published online:
28 September 2022

• References

• 1 Thase ME, Denko T. Pharmacotherapy of mood disorders. Annu Rev Clin Psychol 2008; 4: 53-91
• 2 Rakofsky J, Rapaport M. Mood Disorders. Continuum (Minneap Minn) 2018; 24: 804-827
• 3 James SL, Abate D, Abate KH. et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017. Lancet 2018; 392: 1789-1858
• 4 Berk M. Pathways to new drug discovery in neuropsychiatry. BMC Med 2010; 10: 151
• 5 Torrey EF, Davis JM. Adjunct treatments for schizophrenia and bipolar disorder. Clin Schizophr Relat Psychoses 2012; 5: 208-216
• 6 Lee HM, Kim Y. Drug repurposing is a new opportunity for developing drugs against neuropsychiatric disorders. Schizophr Res Treatment 2016; 2016: 6378137
• 7 Kidnapillai S, Bortolasci CC, Udawela M. et al. The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. World J Biol Psychiatry 2020; 21: 775-783
• 8 Robinson MD, McCarthy DJ, Smyth GK. edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139-140
• 9 Huang DW, Sherman BT, Tan Q. et al. The DAVID gene functional classification tool. Genome Biol 2007; 8: R183
• 10 Subramanian A, Narayab R, Corsello SM. et al. A next generation connectivity map. Cell 2017; 171: 1436-1452
• 11 Pasco JA, Nicholson GC, Kotowicz MA. Cohort profile: Geelong Osteoporosis Study. Int J Epidemiol 2012; 41: 1565-1575
• 12 Williams LJ, Jacka FN, Pasco JA. et al. The prevalence of mood and anxiety disorders in Australian women. Australas Psychiatry 2010; 18: 250-255
• 13 First MB, Spitzer RL, Gibbon M. et al. Scrutcured Clinical Interview for DSM-IVRT Axis I Disorders, Research Versions, Non-Patient Edition. New York Biometrics Research: New York State Psychiatric Institute. 2002
• 14 Nes WD. Biosynthesis of cholesterol and other sterols. Chem Rev 2011; 111: 6423-6451
• 15 Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 2015; 6: 254-264
• 16 Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell Neurosci 2005; 29: 190-201
• 17 Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev 2007; 31: 858-873
• 18 Duman RS, Malberg J, Nakagawa S. et al. Neuronal plasticity and survival in mood disorders. Biol Psychiatry 2000; 48: 732-739
• 19 Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev 2014; 94: 355-382
• 20 Feldman AZ, Shrestha RT, Hennessey JV. Neuropsychiatric manifestations of thyroid disease. Endocrinol Metab Clin North Am 2013; 42: 453-476
• 21 Krishna VN, Thunga R, Unnikrishnan B. et al. Association between bipolar affective disorder and thyroid dysfunction. Asian J Psychiatr 2013; 6: 42-45
• 22 Cole DP, Thase ME, Mallinger AG. et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002; 159: 116-121
• 23 Hage MP, Azar ST. The link between thyroid function and depression. J Thyroid Res 2012; 2012: 590648
• 24 Thomsen AF, Kvist TK, Andersen PK, Kessing LV. Increased risk of developing affective disorder in patients with hypothyroidism: A register-based study. Thyroid 2005; 15: 700-707
• 25 Pushpakom S, Iorio F, Eyers PA. et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov 2019; 18: 41-58
• 26 McElroy SL, Dessain EC, Pope HG. et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991; 52: 411-414
• 27 Ranjan R, Meltzer HY. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40: 253-258
• 28 Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder. Bipolar Disord 2012; 14: 863-869
• 29 Rosenblat JD, Cha DS, Mansur RB. et al. Inflamed moods: A review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2014; 53: 23-34
• 30 Berk M, Williams LJ, Jacka FN. et al. So depression is an inflammatory disease, but where does the inflammation come from?. BMC Medicine 2013; 11: 200
• 31 Pasco JA, Nicholson GC, Williams LJ. et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psych 2010; 197: 372-377
• 32 Arabzadeh S, Ameli N, Zeinoddini A. et al. Celecoxib adjunctive therapy for acute bipolar mania. Bipolar Disord 2015; 17: 606-614
• 33 Williams LJ, Pasco JA, Mohebbi M. et al. Statin and aspirin use and the risk of mood disorders among men. Int J Neuropsychopharmacol 2016; 19: pyw008
• 34 Kohler O, Benros ME, Nordentoft M. et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects. JAMA Psychiatry 2014; 71: 1381-1391
• 35 Pasco JA, Jacka FN, Williams LJ. et al. Clinical implications of the cytokine hypothesis of depression. Psychother Psychosom 2010; 79: 323-325
• 36 Guo M, Mi J, Jiang QM. et al. Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin Exp Pharmacol Physiol 2014; 41: 650-656
• 37 Wang CP, Lorenzom C, Habib SL. et al. Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. J Diabetes Complications 2017; 31: 679-686
• 38 Wahlqvist ML, Lee M, Chuang S. et al. Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination. BMC Medicine 2012; 10: 150
• 39 Calkin CV, Chengappa KNR, Cairns K. et al. Treating insultin resistance with metformin as a stratefy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD Study). J Clin Psychiatry 2022; 83: 2
• 40 Abdallah MS, Mosalam EM, Zidan AA. et al. The antidiabetic metformin as an adjunct to antidepressants in patients with major depressive disorder. Neurotherapeutics 2020; 17: 1897-1906
• 41 Hayes JF, Lundin A, Wicks S. et al. Association of hydroxylmethyl glutaryl coenzyme A reductase inhibitors, L-type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness. JAMA Psychiatry 2019; 76: 382-390
• 42 Calkin CV, Gardner DM, Ransom T. et al. The relationship between bipolar disorder and type 2 diabetes: More than just co-morbid disorders. Ann Med 2013; 45: 171-181
• 43 Cynthia V, Calkin CV, Ruzickova M. et al. Insulin resistance and outcome in bipolar disorder. Br J Psychiatry 2015; 206: 52-57
• 44 Janus A, Szahidewicz-Krupska E, Mazur G. et al. Insulin resistance and endothelial dysfunction constitute a common therapeutic target in cardiometabolic disorders. Mediators Inflamm 2016; 2016: 3634948
• 45 Kang HS, Cho HC, Lee JH. et al. Metformin stimulates IGFBP-2 gene expression through PPARalpha in diabetic states. Sci Rep 2016; 6: 23665
• 46 Zhao Y, Wei X, Song J. et al. Peroxisome proliferator-activated receptor γ agonist rosiglitazone protects blood-brain barrier integrity following diffuse axonal injury by decreasing the levels of inflammatory mediators through a caveolin-1-dependent pathway. Inflammation 2019; 42: 841856
• 47 Li J, Shan Z, Yang W. et al. Gender-differential effects on blood glucose levels between acarbose and metformin in Chinese patients with newly diagnosed type 2 diabetes. Endocr J 2021; 68: 69-79